** Shares of cancer drugmaker Exelixis EXEL.O rise 5.6% to $39 premarket

** Co late on Tuesday raised 2025 rev. forecast to between $2.25 billion and $2.35 billion, compared with prior view of between $2.15 billion and $2.25 billion

** Co posted Q1 total rev. of $555.4 million, beating analysts' estimate of $498.2 million - data compiled by LSEG

** Co posted Q1 adj. profit of 62 cents per share vs estimates of 36 cents per share on sales of its cancer drug, Cabometyx

** As of last close, stock up 11% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))